High-grade gliomas (HGGs) are extremely aggressive primary brain tumors with high mortality rates. Despite notable advancements in clinical research, HGGs are still characterized by poor prognosis and appalling survival rates. Several global proteomics studies have reported many protein biomarkers however, the transition of these proteins biomarkers from lab to clinic is exceptionally low. In the current study, over-expressed HGG proteins identified from various global proteomics studies were validated in HGG tissue samples to explore their role as potential therapeutic candidates.